Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Table 1 Studies for pancreatic cancer

	n	Age	No. of hepatic metastases	Median size of liver metastases	Chemotherapy	Mortality rate
Hackert et al[39], 2017	85	60	96% had 3 lesions 3 had > 3 lesions	31% had 1-2 cm 43% had < 1 cm	74% received Adjuvant gemcitabine or 5 FU	2.90%
Crippa et al[34], 2016	11	65 (35-80)	10% had 1 28% had 1-5 61% had > 5	NA	Neoadjuvant gemcitabine (14%), 30% gemcitabine + nab-paclitaxel while 66% had FOLFIRINOX, PEFG, PEXG or PDXG	0
Tachezy et al[38], 2016	69	65 (31-83)	2 (1-11)	NA	Neoadjuvant gemcitabine in 4% or FOLFIRINOX in 14%. Adjuvant in 80%, 80% got gemcitabine and 7% FOLFIRINOX	1%
Zanini et al[35], 2015	15	55 (52-64)	2 (1-3) 60% had 1 lesion	2.2 cm (1.8-2.5)	Adjuvant gemcitabine	0
Klein et al[33], 2012	22	57.5 (31-78)	NA	NA	Adjuvant gemcitabine	0
Dünschede et al[40], 2010	9	55 (39-72)	3 (1-5)	3.5 (1-9)		0
Gleisner et al[37], 2007	17	64.7 ± 11.4	1 (1-1)	0.6 (0.3-1.2)	6 received 5FU or gemcitabine	9.10%
Shrikhande et al[36], 1996	11	65 (60-74)	2 (1-3)	NA	Adjuvant Gemcitabine or 5FU or radiation	0

5FU: Fluorouracil; FOLFIRINOX: Oxaliplatin, irinotecan, fluorouracil and leucovorin, cisplatin; PEXG: Gemcitabine plus capecitabine and epirubicin; PDXG: Capecitabine and docetaxel; PEFG: Epirubicin and fluorouracil; NA: Not available.